Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$982.00K$982.00K−41.8% vs Q3 2017 Net Income$66.73M$66.73M+365.9% vs Q3 2017 EPS Diluted$0.53$0.53+341.7% vs Q3 2017 Gross Profit$947,000−42.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,332,000N/M Free Cash Flowderived-$7,494,000N/M Margins · derivedGross margin96.4%−0.5 pt vs Q3 2017
Operating margin-1054.7%−491.1 pt vs Q3 2017
Net margin6794.8%
ended Sep 30, 2018 · filed Nov 8, 2018 · 39 d after period end